SurVaxM is a cancer immunotherapy vaccine (boosts the body’s own immune system to fight cancer cells) designed to target and attack cancer cells with survivin (an antigen produced in cancer
A major impediment to improving brain tumor outcomes is poor clinical trial accrual. In fact, only 20 percent of neuro-oncology patients enroll in clinical trials. Surveys of brain tumor patients
Preliminary Results of ABTA Metastatic Brain Tumor Initiative Patient and Caregiver Survey Presented at the American Society Clinical Oncology Annual Meeting The American Brain Tumor Association presented preliminary survey
Until recently, drug discovery has traditionally focused on the development of a therapy to treat a specific tumor type based on the origin of the cancer, such as colon cancer,
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest oncology meetings attracting more than 33,000 researchers and medical professionals from around the world. In addition
On Thursday, June 20, six members of the ABTA staff delivered oral statements to Medicare in regard to the issue outlined below. We invite you to review the information and
American Brain Tumor Association
8550 W. Bryn Mawr Ave. Ste 550
Chicago, IL 60631
